While the share price has taken a hit over the last few months,...

While the share price has taken a hit over the last few months, the fundamentals are getting stronger, which presents an even greater opportunity.
When you have a look at some of the deals that have been completed in the past years, it gives you a real perspective into what can happen here.
Merck and Ablynx = 7 billion deal
Bristol-Myers Squibb and Nektar =3.6 billion
Merk and Eisai = 5.7 billion
Repl, Replimune = market cap of 2 billion

Some big buy outs, some big partnerships, and some large market caps for one drug at times.
So if IMU can deliver on three not just one platform, with the chance of multiple drugs and partnerships in each platform, how dose this compare to those figures above.
I would say very favorable indeed. In fact IMHO I pretty sure it would blow those figures above out of the water.
GLTA I think with a little patience we are on to something really special here.